67 results
8-K
EX-99.1
RVMD
Revolution Medicines, Inc.
6 Nov 23
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
4:05pm
expansion programs focused on RAS mutation hotspots including G12R, G13D and other important targets.
Third Quarter 2023 Financial Highlights
Cash
425
7aozccje0iqydl0
23 Oct 23
Business combination disclosure
6:13am
DEFM14A
hfm924hk87sun 0ub8
29 Sep 23
Proxy related to merger
4:19pm
424B3
vr8d2yr1o5azi
29 Sep 23
Prospectus supplement
4:17pm
S-4/A
ppater e1ppz7a167d
27 Sep 23
Registration of securities issued in business combination transactions (amended)
5:25pm
S-4
3xac7hn9vjhqut5jb56
13 Sep 23
Registration of securities issued in business combination transactions
5:20pm
8-K
EX-99.1
vv98p0a
8 Aug 23
Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress
4:04pm
425
k188oh0dfs6fjntg56
1 Aug 23
Business combination disclosure
5:22pm
425
eyuondqbl1
1 Aug 23
Business combination disclosure
5:11pm
425
haq5d25qwh9m
1 Aug 23
Business combination disclosure
5:09pm
425
hss2kw5xlfk7jesk
1 Aug 23
Business combination disclosure
7:15am
8-K
EX-99.2
wj3u 7r0r
1 Aug 23
Form of Parent Stockholder Voting Agreement
7:10am
8-K
EX-99.1
6f05m5jpf4 6dn
8 May 23
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress
4:04pm